CM
TNDM icon

Castleark Management’s Tandem Diabetes Care TNDM Stock Holding History

Castleark Management’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-78,180
Closed -$9.09M – 342
2022
Q1 		$9.09M Buy
78,180
+4,380
+6% +$511K 0.39% 53
2021
Q4 		$11.1M Buy
73,800
+42,810
+138% +$5.78M 0.41% 59
2021
Q3 		$3.7M Buy
+30,990
New +$3.41M 0.14% 153
2020
Q4 		– Sell
-131,850
Closed -$15M – 365
2020
Q3 		$15M Buy
131,850
+30,065
+30% +$3.16M 0.59% 42
2020
Q2 		$10.1M Buy
101,785
+14,370
+16% +$1.15M 0.44% 51
2020
Q1 		$5.63M Buy
+87,415
New +$6.12M 0.33% 85
2019
Q4 		– Sell
-59,971
Closed -$3.54M – 390
2019
Q3 		$3.54M Sell
59,971
-76,170
-56% -$4.86M 0.14% 172
2019
Q2 		$8.78M Sell
136,141
-15,925
-10% -$1.03M 0.34% 100
2019
Q1 		$9.66M Sell
152,066
-128,114
-46% -$6.73M 0.36% 88
2018
Q4 		$10.6M Sell
280,180
-71,670
-20% -$2.53M 0.45% 57
2018
Q3 		$15.1M Sell
351,850
-103,320
-23% -$3.61M 0.43% 78
2018
Q2 		$10M Buy
+455,170
New +$5.6M 0.31% 109

Other funds holding TNDM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Castleark Management's TNDM Position: Q2 2022 in Review

Castleark Management sold out of Tandem Diabetes Care (TNDM) in Q2 2022, closing a stake of 78,180 shares — an estimated $9.09M sold.

Castleark Management first reported a position in TNDM in Q2 2018 and held it in 12 quarters. The position peaked at $15.1M in Q3 2018. 330 funds tracked by Wall St. Rank hold TNDM as of Q2 2022.

  • Castleark Management reported no remaining Tandem Diabetes Care position as of Q2 2022 after selling out during the quarter.
  • Castleark Management sold 78,180 Tandem Diabetes Care shares in Q2 2022, an estimated $9.09M.
  • Castleark Management first reported a position in Tandem Diabetes Care in Q2 2018 and held it in 12 quarters.
  • Castleark Management's Tandem Diabetes Care position peaked at $15.1M in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2022.

Based on Castleark Management's 13F filing for Q2 2022, filed 16 Aug 2022.